Adipose beiging benefits

Body composition
& metabolism.

Characterization of the active compounds

The active compounds in the formula of Sinetrol® have been heavily characterized. An HPLC is run on each batch to ensure the polyphenols in Sinetrol® are available at the same dose as proven in our clinical studies.

Active Compounds

Primary active compounds:
          Naringin
          Hesperidin
Both expressed as flavanones > 40%

Secondary active compounds:
Other flavanones, caffeine

NARINGIN
HESPERIDIN

BOTANICAL SOURCES

Grapefruit extracts
Citrus grandis (L.) Osbeck, Citrus paradisi Macfad
Orange extract
Citrus sinensis (L.) Osbeck
Guarana extract
Paullinia cupana Kunth
Formulation
Recommended daily dosage: 630 mg

Science supporting Sinetrol®

More than 10 years of research have been conducted to support the mechanism of action and clinical benefits of Sinetrol® on body composition.

IN VITRO
PRE-CLINICAL STUDIES
PILOT CLINICAL STUDIES
PIVOTAL CLINICAL STUDIES
Sinetrol® is a patented ingredient studied in over 300 subjects and its benefits have been demonstrated using gold-standard methodology during interventional studies with follow-up.

Mechanism of action

Adipose tissue: regulation of fat stores through lipolysis

White adipose tissue (WAT) plays a critical role in whole body energy homeostasis. It stores excess energy in the form of triglycerides and releases fatty acids via lipolysis. The ratio between WAT and brown adipose tissue (BAT) regulates the level of energy expenditure, which is unbalanced in overweight and obese people.
Beiging of adipose tissue confers beneficial effects, increase the energy expenditure at the cellular level.

Sinetrol® works at the adipocyte level

1/ Sinetrol® enhances physiological lipolysis through PDE-inhibition.

Increase in cAMP level enhances physiological lipolysis.

2/ Sinetrol® intensifies FFA metabolization through promotion of the expression of mitochondrial uncoupling proteins (UCPs).

Increase in cAMP level induced by Sinetrol® promotes higher expression of UCPs as in beige adipose tissue.

Pivotal clinical studies

Locations

Murcia, Spain
Clinical facility, UCAM

Seoul, Republic of Korea
Kangbuk Samsung Hospital

Year & Duration

2017
20 weeks (16+4)

2019
12 weeks

Populations

77 subjects
Caucasian population
BMI: 25-40 kg/m2
Age: 29-52 years old

86 subjects
Asian population
BMI: 24-30 kg/m2
Age: 25-62 years old

Protocols

Body composition
DXA scan

Recommended individualized
normo-caloric diet 
(Harris and Benedict) 

Body composition
DXA scan

Recommended
hypo-caloric diet
(-500 kcal hypocaloric diet)

Intakes

CAPSULES 
2 x 450 mg/day 

TABLETS
1 x 900 mg/day 

Locations

Murcia, Spain
Clinical facility,
UCAM, University of Murcia 

Seoul, Republic of Korea
Kangbuk Samsung Hospital

Year & Duration

2017
20 weeks (16+4)

2019
12 weeks

Populations

77 subjects
Caucasian population
BMI: 25-40 kg/m2
Age: 29-52 years old

86 subjects
Asian population
BMI: 24-30 kg/m2
Age: 25-62 years old

Protocols

Body composition
DXA scan

Recommended individualized
normo-caloric diet 
(Harris and Benedict) 

Body composition
DXA scan

Recommended
hypo-caloric diet
(-500 kcal hypocaloric diet)

Intakes

CAPSULES 
2 x 450 mg/day 

TABLETS
1 x 900 mg/day 

Primary outcome: body fat mass reduction

Body composition is rebalanced: lean-to-fat mass ratio significantly improves with Sinetrol®.
65% of the total fat loss was from the trunk area: Index of Central Obesity decreases significantly.
Waist & hip lines significantly decrease.

Long-lasting benefits

A 1-month follow-up after the end of the supplementation confirms that the effect of Sinetrol® on metabolism provides durable benefits on body composition:
  • Subjects continue to lose body weight.
  • Subjects continue to reduce body fat mass.
KEY OUTCOMES
  • Patented ingredient
  • Proven mechanism of action: adipose beiging benefits
  • Increase in resting energy expenditure
  • Rebalanced body composition: significant reduction of body fat mass without lean mass loss
  • Significant result on body weight, waist and hip lines
  • Long-lasting benefits: Subjects continue to experience adipose beiging benefits

Applications

Commercial name
Sinetrol® Xpur C
Sinetrol® Xpur
COMPOSITION
Citrus and guarana extracts
Citrus and guarana extracts
ACTIVE COMPOUNDS
Flavanones (HPLC, 280 nm)        > 40%
Caffeine                                               3.3-4%
Flavanones (HPLC, 280 nm)        > 20%
Caffeine                                                1-4%
RECOMMENDED DOSAGE
630 mg/day
900 mg/day
APPLICATIONS
Dietary supplements
Dietary supplements
OTHERS
No allergen, non-GMO, halal, gluten-free
No allergen, non-GMO, halal, gluten-free
Commercial name
Sinetrol® Xpur C
Sinetrol® Xpur
COMPOSITION
Citrus and guarana extracts
Citrus and guarana extracts
ACTIVE COMPOUNDS
  • Flavanones (HPLC, 280 nm) > 40%
  • Caffeine 3.3-4%
  • Flavanones (HPLC, 280 nm) > 20%
RECOMMENDED DOSAGE
630 mg/day
900 mg/day
APPLICATIONS
Dietary supplements
Dietary supplements
OTHERS
No allergen, non-GMO, halal, gluten-free
No allergen, non-GMO, halal, gluten-free

An international reach

25+
Sinetrol® being sold in more than 25 countries

AUSTRALIA – BRAZIL – CANADA – CHINA – CZECH REPUBLIC – ENGLAND – FINLAND – FRANCE – GERMANY – HUNGARY – INDIA – INDONESIA – ITALIA – JAPON – LEBANON – MALAYSIA – MEXICO – POLAND – SAN MARINO – SERBIA – SOUTH AFRICA – SPAIN – SWITZERLAND – TAÏWAN – THAÏLAND – USA – VIETNAM

0 +M
daily doses sold in the last 5 years
0 s
of finish products formulated with Sinetrol®
0
Sinetrol® during the past 12 months
0 %
in dry forms
Fill form to contact us
Fill form to receive the brochure
Disclaimer

This website is intended to provide information about Fytexia’s ingredients, used in various dietary supplement products around the world. It is intended to provide information to food supplement professionals and is not designed for the general public. As Fytexia’s ingredients are being marketed in a large number of countries, it is the responsibility of each of our customers to ensure that the use of the ingredient and any claim made in the labeling or advertising of the ingredient comply with the applicable rules and regulations.